

REMARKS

Restriction was required under 35 U.S.C. § 121 and 372 from among the following groups of claims:

Group I, claim(s) 88-93 and 96 (in part), drawn to an isolated coronavirus spike (S) protein.

Group II, claim(s) 88-93 and 96 (in part), drawn to an isolated coronavirus polymerase (pol) protein.

Group III, claim(s) 88-93 and 96 (in part), drawn to an isolated coronavirus hemagglutinin/esterase (HE) protein.

Group IV, claim(s) 94 and 95, drawn to a method of producing an S protein.

Group V, claim(s) 97 (in part) and 98, drawn to a method of making an anti-CRCV S protein antibody.

Group VI, claim(s) 97 (in part) and 100, drawn to a method of making an anti-CRCV HE protein antibody.

Group VII, claim(s) 99, drawn to an anti-S protein antibody.

Group VIII, claim(s) 101, drawn to an anti-HE protein antibody.

Group IX, claim(s) 102-106, 163 (in part) and 107, drawn to a method of screening a dog for S protein specific antibodies.

Group X, claim(s) 102-106, 163 (in part) and 108, drawn to a method of screening a dog for HE protein specific antibodies.

Group XI, claim(s) 102, 109-112, 116-117, 163 (in part) and 113 drawn to a method of identifying S proteins in canine biological samples.

Group XII, claim(s) 102, 109-112, 116-117, 163 (in part) and 114, drawn to a method of identifying pol proteins in canine biological samples.

Group XIII, claim(s) 102, 109-112, 116-117, 163 (in part) and 115, drawn to a method of identifying HE proteins in canine biological samples.

Group XIV, claim(s) 118-124 and 151-156 (in part), drawn to an immunosorbent assay for detecting S protein antibodies.

Group XV, claim(s) 118-124 and 151-156 (in part), drawn to an immunosorbent assay for detecting HE protein antibodies.

Group XVI, claim(s) 125-127 (in part), drawn to a solid substrate with an S protein.

Group XVII, claim(s) 125-127 (in part), drawn to a solid substrate with a HE protein.

Group XVIII, claim(s) 128 and 129 (in part) and 130-131, and 134-136 (in part), drawn to a vaccine composition containing an S protein.

Group XIX, claim(s) 128, 129 and 132 (in part) and 133, and 134-136 (in part), drawn to a vaccine composition containing a HE protein.

Group XX, claim(s) 128, 129, 132 and 134-136 (in part) drawn to a vaccine composition containing an integral membrane protein (M).

Group XXI, claim(s) 137, 138 and 143 (in part), and 139-140, drawn to a use of an S protein.

Group XXII, claim(s) 137, 138, 141 and 143 (in part), and 142, drawn to a use of a HE protein.

Group XXIII, claim(s) 137, 138, 141 and 143 (in part), drawn to a use of an M protein.

Group XXIV, claim(s) 144 (in part), drawn to a method of vaccinating a dog with the vaccine of Group XVIII.

Group XXV, claim(s) 144 (in part), drawn to a method of vaccinating a dog with the vaccine of Group XIX.

Group XXVI, claim(s) 144 (in part), drawn to a method of vaccinating a dog with the vaccine of Group XX.

Group XXVII, claim(s) 145 and 146 (in part), drawn to a method of combating the spread of CRCV between dogs by vaccinating nearby dogs once a dog is identified to as being infected that involves testing the dog for S protein specific antibodies or quarantining the infected dog.

Group XXVIII, claim(s) 145 and 146 (in part), drawn to a method of combating the spread of CRCV between dogs by vaccinating nearby dogs once a dog is identified to as being infected that involves testing the dog for HE protein specific antibodies or quarantining the infected dog.

Group XXIX, claim(s) 145 and 146 (in part), drawn to a method of combating the spread of CRCV between dogs by vaccinating nearby dogs once a dog is identified to as being infected that involves testing a dog for S proteins or quarantining the infected dog.

Group XXX, claim(s) 145 and 146 (in part), drawn to a method of combating the spread of CRCV between dogs by vaccinating nearby dogs once a dog is identified to as being infected that involves testing a dog for pol proteins or quarantining the infected dog.

Group XXXI, claim(s) 145 and 146 (in part), drawn to a method of combating the spread of CRCV between dogs by vaccinating nearby dogs once a dog is identified to as being infected that involves testing a dog for HE proteins or quarantining the infected dog.

Group XXXII, claim(s) 147 (in part), drawn to a method for identifying a test vaccine that involves testing a dog for S protein specific antibodies.

Group XXXIII, claim(s) 147 (in part), drawn to a method for identifying a test vaccine that involves testing a dog for HE specific antibodies.

Group XXXIV, claim(s) 147 (in part), drawn to a method for identifying a test vaccine that involves testing a dog for S proteins.

Group XXXV, claim(s) 147 (in part), drawn to a method for identifying a test vaccine that involves testing a dog for Pol proteins.

Group XXXVI, claim(s) 147 (in part), drawn to a method for identifying a test vaccine that involves testing a dog for HE proteins.

Group XXXVII, claim(s) 148, drawn to a CIRD vaccine.

Group XXXVIII, claim(s) 149 and 150, drawn to an E. coli expressing a spike protein of CRCV and a plasmid containing the spike protein.

Group XXXIX, claim(s) 157, 158, 160, 161 and 159 and 162 (in part), drawn to a method of passively immunizing a dog with anti-S protein antibodies.

Group XXXX, claim(s) 157, 158, 160, 161 and 159 and 162 (in part), drawn to a method of passively immunizing a dog with anti-HE antibodies.

Response to Restriction Requirement

In response to the Restriction Requirement, Applicant elects Group XVIII, drawn to a vaccine composition (Claims 128-131 and 134-136, in part). New Claims 164 and 165 also belong to Group XVIII because they are dependent on and incorporate all of the limitations of Claim 128. Support for new claims 164 and 165 is found in the Specification as filed, for example at page 53, second and third paragraphs.

Application No.: 10/522,513
Filing Date: June 22, 2006

Request for Rejoinder

Upon allowance of Group XVIII claims, Applicant respectfully requests rejoinder of withdrawn Claim 144, which is dependent on the elected Group XVIII claims and includes all of the limitations of Claim 128.

No Disclaimers or Disavowals

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, the Applicants are not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. The Applicants reserve the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that the Applicants have made any disclaimers or disavowals of any subject matter supported by the present application.

Co-Pending Applications of Assignee

Applicant wishes to draw the Examiner's attention to the following co-pending applications of the present application's assignee.

Serial Number	Title	Filed
10/563,199	VACCINE COMPOSITION FOR VACCINATING DOGS AGAINST CANINE INFECTIOUS RESPIRATORY DISEASE (CIRD)	01-Sep-2006
11/849,931	VACCINE COMPOSITION FOR VACCINATING DOGS AGAINST CANINE INFECTIOUS RESPIRATORY DISEASE (CIRD)	04-Sep-2007


Application No.: 10/522,513
Filing Date: June 22, 2006

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 2 September 2008

By: 
Raymond D. Smith
Registration No. 55,634
Agent of Record
Customer No. 20995
(949) 760-0404

5846575
082608